Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Millennium Pharmaceuticals, Inc
Femme Max 99 ans
Millennium Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
To estimate the objective antitumor response rate of MLN8237 using the Response Evaluation Criteria in Solid tumors (RECIST criteria) or CA 125 criteria in patients with platinum-refractory or platinu...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Millennium Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis
The primary objectives of this study are to: •Determine the safety and tolerability of MLN1202 in patients with RRMS. •Determine the efficacy of MLN1202 in patients with RRMS by comparing the mean num...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Millennium Pharmaceuticals, Inc
MAJ Il y a 4 ans
Study to find out the effects and fate of treatment with Orteronel plus prednisone in Japanese and non Japanese people that have not recieved cancer therapy for prostate cancer
To determine whether orteronel 300 mg twice daily (BID) plus prednisone 5 mg BID more effectively reduces serum testosterone levels, compared to placebo plus prednisone 5 mg BID, when administered to ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Millennium Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohns Disease
To determine the safety profile of long-term MLN0002 treatment
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Millennium Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Study of Vedolizumab for Treatment of Graft-Versus-Host Disease (GvHD) that has not responded to steroid treatment in patients who have had stem cell transplantation
The primary objective is to describe the initial activity, tolerability, and safety and to identify a recommended dose and regimen of vedolizumab IV administered for treatment of steroid-refractory ac...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Millennium Pharmaceuticals, Inc
MAJ Il y a 4 ans
Study of the drug substances MLN0128, MLN0128+MLN1117, Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 the Treatment of Patients with Endometrial Cancer
To determine if MLN0128 in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Millennium Pharmaceuticals, Inc
MAJ Il y a 4 ans
Phase 4 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Studie fáze 4 s Brentuximab Vedotinem u pacientů s relabujícím nebo refrakterním Hodgkinovým lymfomem, kteří nejsou vhodní k transplantaci kmenových buněk nebo multiagentní chemoterapii
To assess the antitumor efficacy, as determined by the objective response rate (ORR) of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 weeks, in patients with rel...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Millennium Pharmaceuticals, Inc
MAJ Il y a 4 ans
Study to determine whether ixazomib as maintenance therapy has an effect on progression free survival and compared to placebo in patients with newly diagnosed multiple myeloma who have not been treated with stem-cell transplantation
To determine the effect of ixazomib maintenance therapy on progression-free survival (PFS), defined as the time from randomization to progressive disease (PD) or death from any cause, compared with pl...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Millennium Pharmaceuticals, Inc
MAJ Il y a 4 ans
Study of Brentuximab Vedotin in Children and Adolescents With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma Studio su vedotin brentuximab in bambini e adolescenti con linfoma a grandi cellule anaplastico sistemico o linfoma di Hodgkin recidivo o refrattario
Phase 1: •To assess the safety profile and determine the pediatric maximum tolerated dose and/or recommended phase 2 dose of brentuximab vedotin •To assess the pharmacokinetics of brentuximab vedo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Millennium Pharmaceuticals, Inc
MAJ Il y a 4 ans
Study to find out whether treatment with orteronel plus prednisone has any potential effects on the heart, by looking at certain heart waves, called QT waves, using an electrocardiogram (ECG) machine
To evaluate the effects of orteronel, when administered with prednisone, on the QT/QTc interval in patients with metastatic castration-resistant prostate cancer (mCRPC)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
Suivant